The FDA's commitment to a fast-track review and recognition of the drug shortage significantly de-risks the remaining packaging deficiency. Traders should watch for the company's submission of manufacturer certifications and any subsequent FDA approval announcement. Approval could unlock a new revenue stream for NRx in a market with limited U.S.-based supply.
Price Chart
Executive Summary
NRx Pharmaceuticals disclosed that the FDA completed first-round review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, but identified a single major deficiency related to the vial's luer lock cap. The FDA committed to reinitiate review in the shortest possible cycle, citing ketamine's status on the drug shortage list. Management expects first commercial sales in 2026 if the packaging issue is resolved.
Key Facts
- ANDA for preservative-free ketamine filed September 2025
- FDA advised July 30, 2026: no major drug-related deficiencies on first-round review
- One major deficiency identified: twist-off cap of luer lock vial (container closure concern)
- Clarification meeting held August 6, 2026 with FDA Office of Generic Drugs and CDER leadership
- FDA committed to immediately reinitiate review and complete in shortest-possible cycle
- Ketamine is on the current FDA drug shortage list and recognized as a strategic drug
- Management estimates only 14%-18% of ANDAs achieve approval on first-round review
- Company provided data: 11.9 million doses of similar vials shipped in past 12 months without complaints, returns, or recalls
Financial Impact
No financial figures provided; potential revenue from first-to-market generic preservative-free ketamine in the U.S. if approved
Risk Factors
- FDA may not accept the manufacturer certifications or may require additional data
- Resolution of the vial cap deficiency could take longer than anticipated, delaying first commercial sales beyond 2026
- Competition from other ANDA filers for preservative-free ketamine could erode market opportunity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-026428 |
| Document: 0001437749-26-026428-index-headers.html | 0001437749-26-026428 |
| Document: 0001437749-26-026428-index.html | 0001437749-26-026428 |
| Document: 0001437749-26-026428.txt | 0001437749-26-026428 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.35 $3.16 | ▼ −5.67% | ▼ −8.24% | $2.90 (−13.28%) |
Sep 14, 2026 18d ago | 8-K | $3.49 $3.29 | ▼ −5.73% | ▼ −5.84% | $2.90 (−16.76%) |
Aug 17, 2026 6w ago | 8-K | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 17, 2026 6w ago | Press Release | $3.43 $3.45 | ▲ +0.58% | ▲ +1.77% | $2.90 (−15.31%) |
Aug 7, 2026 8w ago | 8-K | $3.58 $3.27 | ▼ −8.66% | ▼ −9.06% | $2.90 (−18.85%) |
Jul 22, 2026 10w ago | 8-K | $4.48 $3.23 | ▼ −27.90% | ▼ −25.50% | $2.90 (−35.16%) |
Jun 22, 2026 14w ago | Press Release | $3.90 $3.73 | ▼ −4.36% | ▼ −2.29% | $2.90 (−25.51%) |
Jun 5, 2026 17w ago | Press Release | $4.14 $3.84 | ▼ −7.25% | ▼ −7.82% | $2.90 (−29.83%) |
Jun 4, 2026 17w ago | Press Release | $4.14 $3.84 | ▲ +7.25% | ▲ +7.82% | $2.90 (+29.83%) |
Jun 3, 2026 17w ago | Press Release | $4.05 $3.76 | ▲ +7.16% | ▲ +3.34% | $2.90 (+28.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access